



ISSN 0161-5850

# Molecular Immunology

## BOARD OF REGIONAL EDITORS

Chairman  
MICHEL FOUGEREAU  
Marseille, France

STEVE DOWEN  
Seattle, U.S.A.

JANOS GERGELY  
Göd, Hungary

DAVID HOLOWKA  
Ithaca, U.S.A.

RONALD S. NEZLIN  
Rehovot, Israel

TOMIO TADA  
Tokyo, Japan

HEALTH SCIENCES LIBRARY  
University of Wisconsin

AUG 27 1991

1305 Linden Dr.  
Madison, Wis. 53706



Pergamon Press

Oxford · New York · Seoul · Tokyo

**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

# Molecular Immunology

## Board of Regional Editors

Prof. MICHEL FOUGEREAU (Chairman of the Board), *Centre d'Immunologie de Marseille-Luminy, Case 906, 13288 Marseille Cedex 9, France.*

Dr STEVEN DOWER, *Immunex Corporation, 51 University Street, Seattle, WA 98101, U.S.A.*

Dr JANOS GERGELY, *Department of Immunology, L. Eötvös University, Javorka S.u. 14, Göd 2131, Hungary.*

Dr DAVID HOLOWKA, *Department of Chemistry, Cornell University, Ithaca, NY 14853, U.S.A.*

Dr ROALD S. NEZLIN, *Department of Chemical Immunology, The Weizmann Institute of Sciences, Rehovot 76100, Israel.*

Dr TOMIO TADA, *Department of Immunology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.*

## Founding Editor

Prof. DAN H. CAMPBELL

## Advisory Editors

G. I. ABELEV  
*Moscow, U.S.S.R.*

B. H. BARBER  
*Toronto, Canada*

DAVID H. BING  
*Boston, MA, U.S.A.*

GUY BORDENAVE  
*Paris, France*

C. A. BONA  
*New York, NY, U.S.A.*

DENNIS R. BURTON  
*Sheffield, U.K.*

L. WILLIAM CLEM  
*Jackson, MI, U.S.A.*

JOHN E. COLIGAN  
*Bethesda, MD, U.S.A.*

MAURICE COLOMB  
*Grenoble, France*

D. H. CONRAD  
*Richmond, VA, U.S.A.*

GIAMPIETRO CORRADIN  
*Lausanne, Switzerland*

SUSAN E. CULLEN  
*St Louis, MO, U.S.A.*

JOSEPH M. DAVIE  
*Skokie, IL, U.S.A.*

M. P. DIERICH  
*Innsbruck, Austria*

S. ELSAYED  
*Bergen, Norway*

PETER L. EY  
*Adelaide, Australia*

DOUGLAS FEARON  
*Baltimore, MD, U.S.A.*

Z. FISHELSON  
*Rehovot, Israel*

R. FRADE  
*Paris, France*

FRANTISEK FRANEK  
*Praha, Czechoslovakia*

ARNOLD FROESE  
*Winnipeg, Canada*

C. GRANIER  
*Marseille, France*

SEN-ITIROH HAKOMORI  
*Seattle, WA, U.S.A.*

JOHN K. INMAN  
*Bethesda, MD, U.S.A.*

DAVID ISENMAN  
*Toronto, Canada*

M. KAARTINEN  
*Helsinki, Finland*

JEAN-PIERRE KINET  
*Bethesda, MD, U.S.A.*

E. KLEIN  
*Stockholm, Sweden*

MICHEL KLEIN  
*Toronto, Canada*

D. M. KRANZ  
*Urbana, IL, U.S.A.*

M. P. LEFRANC  
*Montpellier, France*

WARREN J. LEONARD  
*Bethesda, MD, U.S.A.*

JOZEF LISOWSKI  
*Wroclaw, Poland*

HENNING LOWENSTEIN  
*Horsholm, Denmark*

J. P. MACH  
*Epalinges, Switzerland*

DAVID G. MARSH  
*Baltimore, MD, U.S.A.*

SHERIE L. MORRISON  
*Los Angeles, CA, U.S.A.*

JIRI NOVOTNY  
*Princeton, NJ, U.S.A.*

EDUARDO A. PADLAN  
*Bethesda, MD, U.S.A.*

ISRAEL PECHT  
*Rehovot, Israel*

CLAUDE DE PREVAL  
*Toulouse, France*

JEAN-LOUIS PREUD'HOMME  
*Poitiers, France*

ROBERT L. RAISON  
*Sydney, Australia*

EVA RAJNAVOLGYI  
*Göd, Hungary*

J. V. RAVETCH  
*New York, NJ, U.S.A.*

WALTER F. RIESEN  
*St Gallen, Switzerland*

KENNETH H. ROUX  
*Tallahassee, FL, U.S.A.*

D. J. ROWLANDS  
*London, U.K.*

CATHERINE SAUTES  
*Paris, France*

VERNE N. SCHUMAKER  
*Los Angeles, CA, U.S.A.*

DAVID M. SEGAL  
*Bethesda, MD, U.S.A.*

B. DAVID STOLLAR  
*Boston, MA, U.S.A.*

JACQUES THEZE  
*Paris, France*

MARC VAN REGENMORTEL  
*Strasbourg, France*

EDWARD W. VOSS, JR  
*Urbana, IL, U.S.A.*

I. YAHARA  
*Tokyo, Japan*

JUNJI YODOI  
*Kyoto, Japan*

D. C. YUAN  
*Dallas, TX, U.S.A.*

*Publishing and Advertising Offices:* Pergamon Press plc, Headington Hill Hall, Oxford OX3 0BW, U.K., and Pergamon Press Inc., 395 Saw Mill River Road, Elmsford, NY 10523, U.S.A. Published monthly. Annual institutional subscription rate (1991) DM 1235.00. Two year institutional rate (1991/92) DM 2346.50. Personal subscription rate for those whose library subscribes at the regular rate (1991) DM 129.00. Subscription enquiries from customers in North America should be sent to: Pergamon Press Inc., 395 Saw Mill River Road, Elmsford, NY 10523, U.S.A., and for the remainder of the world to: Pergamon Press plc, Headington Hill Hall, Oxford OX3 0BW, U.K. Subscription rates for Japan include despatch by air and prices are available on application. Prices are subject to change without notice.

## Microform Subscriptions and Back Issues

Back issues of all previously published volumes, in both hard copy and on microform, are available direct from Pergamon Press offices.

Copyright © 1991 Pergamon Press plc

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organizations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature, and translation. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

**Photocopying information for users in the U.S.A.** The Item-fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying, beyond that permitted by Section 107 or 108 of the United States Copyright Law, is paid. The appropriate remittance of \$3.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970.

**Permission for other use.** The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying.

*The Item-Fee Code for this publication is:* 0161-5890/91 \$3.00 + 0.00

Whilst every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinion or statement appears in this journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the sole responsibility of the contributor or advertiser concerned. Accordingly, the publishers, the editorial board and editors and their respective employees, officers and agents accept no responsibility or liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

™ The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

## Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2

David B. Ring<sup>1</sup>, Robin Clark and Amita Saxena

Departments of Immunology [DR] and Molecular Biology [RC, AS]  
Cetus Corporation, Emeryville, CA 94068

(First received 12 December 1990; accepted 3 May 1991)

### Abstract

BCA200 has been described as a 200,000 Mr monomeric cell surface glycoprotein associated with human breast cancer. Since the physical properties and cellular distribution of BCA200 resemble those of c-erbB-2, antibodies to BCA200 were tested for the ability to bind a recombinant protein containing the c-erbB-2 extracellular domain (erbB-2 ECD). Three antibodies to distinct epitopes of BCA200 reacted with erbB-2 ECD but not with a control protein expressed in a similar baculovirus lysate. Control myeloma proteins and antibodies to four other antigens did not react with erbB-2 ECD. A protein with the expected molecular weight for erbB-2 ECD was also immunoprecipitated by anti-BCA200 antibody 520C9. We conclude that BCA200 is another synonym for c-erbB-2.

### Introduction

C-erbB-2 or HER-2 is a human proto-oncogene homologous to the rat neu oncogene and related in sequence to human erbB-1 or epidermal growth factor receptor (Coussens et al., 1985; Bargmann et al., 1986; Yamamoto et al., 1986). It encodes a 185-190,000 dalton protein product with extracellular, transmembrane and tyrosine kinase domains (Akiyama et al., 1986; Yamamoto et al., 1986). Normal c-erbB-2 product has transforming activity when over-expressed, as do several mutant gene products with amino acid substitutions in the transmembrane region (Di Fiore et al., 1987; Slamon et al., 1989). Gene amplification and protein level over-expression of c-erbB-2 have been observed in a wide variety of human adenocarcinomas and correlated with metastasis and poor prognosis (Slamon et al., 1987, 1989; Berger et al., 1988; Zhou et al., 1987).

Recently, one of us described BCA200, an approximately 200,000 M<sub>r</sub> glycoprotein recognized by a number of mouse monoclonal antibodies raised against human breast cancer (Ring et al., 1989). In discussing the relationship of BCA200 to known tumor-associated antigens, we noted that a polyclonal rabbit serum against c-erbB-2 did not capture antigen recognized by our BCA200 antibodies. However, many properties of BCA200 (Mr, monomeric glycoprotein structure, expression levels on particular cell lines, tumor types and normal human tissues) resembled those reported for c-erbB-2, leading us to question the negative result of the antigen capture experiment. (We were concerned that the polyclonal capture antibody was not affinity purified, and may actually have captured very little c-erbB-2). We have now carried out experiments showing that antibodies to three distinct epitopes on BCA200 react with a recombinant protein containing the extracellular domain of c-erbB-2.

### Materials and Methods

**PCR subcloning of the c-erbB-2 extracellular domain (erbB-2 ECD).** cDNA template was prepared by reverse transcription of mRNA from tumor T882 (a gift of Dennis Slamon, UCLA). The cDNA was synthesized by using murine leukemia virus reverse transcriptase (Bethesda Research Laboratories) according to the manufacturer's protocol. The 20 µl reaction mixture contained the enzyme buffer as supplied, 0.5 µg RNA, 10 units of RNasin (Promega Biotech, Madison, WI), 10 pmol of 3' PCR primer (CAGTCTAGATTTTCAGGATCCGCATCTGCGC), 1 mM (each) deoxynucleoside triphosphates, and 100 units of reverse transcriptase. The reaction mixture was incubated for 30 min at 37 °C. For amplification (Mullis & Faloona, 1987; Salki et al., 1985) 4 µl of the reaction mixture was then diluted into 100 µl PCR buffer (10 mM Tris pH 8.4, 2.5 mM MgCl<sub>2</sub>, 50 mM KCl, 100 µg/ml BSA) containing 100 µM dNTP's, 1 pmol of each primer and 0.5 unit of thermostable DNA polymerase from *Thermus aquaticus* (Taq polymerase; Chien et al., 1976; Salki et al., 1988). The reaction was started by denaturing the RNA cDNA hybrid by heat (95 °C) for 1 min, annealing the primers for 1 min at 55 °C, and then extending the primers at 72 °C for 3 min. This cycle was repeated 25 times using a programmable heat block designed and manufactured by Cetus Corporation (Emeryville, CA). After the final cycle, the temperature was held at 72 °C for 10 min to allow reannealing of the amplified products and then was chilled. PCR amplification of the 5' half erbB-2 ECD coding sequence was directed by the 5' primer GCACCATGGAGCTGGCGGCC and the 3' primer GCACTTCTCACACCGCTGTGTTC. Amplification

<sup>1</sup>To whom correspondence should be addressed

This material may be protected by Copyright law (Title 17 U.S. Code)

of the 3' half erbB-2 ECD coding sequence was directed by the 5' primer CGGACGTGGGATCCTGCACCCTCGTCTGC and the 3' primer CCTGGTACCTTATGTTTCAGGTTTCAGGAGGAGGTGTGCCGGACGTCAGAGGGCTGGCTCTGCTCG. (Underlined nucleotides encode the KT3 epitope.) Products obtained after amplification were inserted between the NcoI and EcoRI sites of baculovirus transfer vector pAcC4 (Luckow and Summers, 1988) to produce the transfer vector pAcNU2. Sequencing of the cloned PCR product revealed three alterations in coding sequence (F 173 to L, L 608 to P, I 613 to V) compared to the previously published sequence (Coussens *et al.*, 1985). These three changes are likely to be artifacts of PCR amplification.

#### Expression of erbB-2 ECD in insect cells.

Sequence encoding erbB-2 ECD was recombined into the *Autographa californica* baculovirus (AcNPV) via the transfer vector pAcNU2. To generate recombinant virus, 2 µg of transfer vector was co-transfected with 1 µg of wild type viral DNA into Sf9 cells as described (Summers and Smith, 1987). Recombinant virus (occlusion-negative) was isolated from the transfection supernatant by plaque purification (Smith *et al.*, 1983). To produce recombinant proteins, Sf9 cells were infected with 5-10 PFU of recombinant virus per cell. Suspension cultures were grown in a stirred flask containing protein-free medium (Maiorella *et al.*, 1988). The cells were infected at  $1-1.5 \times 10^6$  cells per ml and were harvested at 48 hr post-infection. The expression level of recombinant protein was approximately 0.4 mg/l of Sf9 culture.

**Monoclonal antibodies.** Murine monoclonal antibodies 106A10 (IgG<sub>1</sub>), 113F1 (IgG<sub>3</sub>), 454A12 (IgG<sub>1</sub>), 454C11 (IgG<sub>2a</sub>), 520C9 (IgG<sub>1</sub>) and 758G5 (IgG<sub>1</sub>) resulted from immunizations with human breast carcinoma cell lines or membrane preparations, and were purified from mouse ascites as previously described (Frankel *et al.*, 1985). Murine hybridoma 3G8 (IgG<sub>1</sub>) (Unkeless, 1979) was obtained from Dr. Jay Unkeless and antibody was purified from mouse ascites by size exclusion and anion exchange chromatography. Murine hybridoma KT3 (IgG<sub>1</sub>) (McArthur and Walter, 1984) was obtained from Gernot Walter and KT3 antibody was purified by anion exchange. MOPC21 and RPC5 myeloma proteins were obtained from Zymed Laboratories, South San Francisco, CA; horseradish peroxidase conjugates of monoclonal antibodies were also prepared by Zymed.

**Immunoprecipitation of erbB-2 ECD by KT3 and 520C9 monoclonal antibodies.** KT3-Sepharose was prepared by absorbing KT3 monoclonal antibody (McArthur and Walter, 1984) to protein-G Sepharose (5-8 mg KT3 per ml resin) and then cross-linking with dimethyl pimelimidate (Schneider *et al.*, 1982). Supernatants from AcNU2 or control-infected Sf9 cells were concentrated 10-fold and dialyzed 10-fold into PBS using 30 kilodalton Centri-prep (Amicon) dialyzers. They were then incubated with 8 µl KT3 Sepharose and 5 µg 520C9 or MOPC-175 myeloma protein or no addition for 1 hr at room temperature and 1 hr at 4 °C. 8 µl protein-G Sepharose (Pharmacia) was added after the first hour. The Sepharose beads were washed 4 times with 1 ml 20 mM Tris pH 8, 150 mM NaCl, 0.5% NP40 and extracted with SDS PAGE sample buffer. Extracted proteins were resolved by SDS polyacrylamide (8%) gel electrophoresis and visualized by Coomassie blue staining.

**ELISA.** A polyvinyl chloride microtiter plate was coated overnight with KT3 antibody at 10 µg/ml in 50 mM NaHCO<sub>3</sub> pH 9.5. After three rinses in PBS, wells were incubated 1 hour in 50 µl PBS or Sf9 cell supernatant containing recombinant c-erbB-2 or M-CSF protein. After another three rinses in blocking solution (10% heat inactivated fetal bovine serum, 2% normal mouse serum, 1% nonfat dry milk, 1% bovine serum albumin in PBS), wells were incubated 1 hour in 50 µl blocking solution containing antibody-peroxidase conjugates at 1 µg/ml. After four final PBS rinses, wells were developed with tetramethylbenzidine substrate and absorbances were read at 450 nm as described (Sheldon *et al.*, 1986). All operations were conducted at room temperature.

#### Results and Discussion

cDNA encoding the extracellular domain of c-erbB-2 (erbB-2 ECD) was synthesized from tumor-derived mRNA by polymerase chain reaction (PCR; Mullis & Faloona, 1987; Saiki *et al.*, 1985) and cloned into a baculovirus transfer vector (pAcC4; Luckow and Summers, 1988). At the 3' end of this c-erbB-2 fragment, DNA encoding the late T antigen epitope (TPPPEPET or "Tag peptide") was added (Figure 1). This epitope is recognized by the monoclonal antibody KT3 (McArthur and Walter, 1984). erbB-2 ECD was expressed in Sf9 insect cells using the AcNPV baculovirus expression system (Smith *et al.*, 1983; Summers and Smith, 1987; Luckow and Summers, 1988). A 90 Kd protein was specifically immunoprecipitated by KT3 from supernatants from Sf9 cells infected with erbB-2 ECD encoding virus (AcNU2) but not from control-infected cells (Figure 2). The identity of this protein was confirmed by N-terminal sequence analysis. (Note that Figure 2 shows Coomassie blue staining of precipitating antibodies as well as immunoprecipitated antigens.)

Figure 3 shows the reactivity of various antibody probes with erbB-2 ECD. Microtiter wells were coated with antibody KT3, and subsequently incubated with AcNU2 supernatant containing erbB-2 ECD or with a similar infected Sf9 supernatant containing recombinant M-CSF. Antibodies 454C11, 520C9 and 758G5 recognize different antigenic determinants on BCA200 (Ring *et al.*, 1989) and MOPC21 and RPC5 are isotype-matched myeloma proteins without known binding specificities. 106A10 and 113F1 respectively immunoprecipitate a 55,000 M<sub>r</sub> glycoprotein and a 40/60/100/200,000 M<sub>r</sub> set of glycoproteins (D. Ring, unpublished data); 454A12 recognizes human transferrin receptor




Figure 1. Construction of the cloned extracellular domain of c-erbB-2 (erbB-2 ECD).



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.